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Human papillomaviruses (HPVs) are responsible for an
enormous global burden of genital disease. HPV is
annually associated with 500,000 new cases of cervical
cancer and 250,000 cervical cancer deaths worldwide.
There are more than 130 HPV genotypes that have been
recognized from various clinical lesions. HPV types 16
and 18 are found in the majority of cervical cancer
cases. The association between HPV infection and cervi-
cal cancer indicates that HPV serves as an ideal target
for development of preventive and therapeutic vaccines.
HPV genome codes eight early or regulatory proteins
(E1-E8) and two late or capsid proteins (L1/L2). Two
HPV oncogenic proteins, E6 and E7, are consistently co-
expressed in HPV-expressing cervical cancers and are
important in the induction and maintenance of cellular
transformation. Therefore, immunotherapy targeting E6
and/or E7 proteins provides an opportunity to prevent
and treat HPV-associated cervical malignancies. Effective
therapeutic HPV vaccines should generate strong E6/E7-
specific T cell-mediated immune responses. Currently,
we have focused on different vaccine modalities includ-
ing DNA vaccines, protein vaccines, live vaccines and
the combined approaches (e.g., prime-boost vaccines)
against HPV infections. In our studies, various strategies
were applied to enhance DNA vaccine potency including
the utilization of adjuvants especially heat shock pro-
teins (e.g., GP96) and delivery systems such as polyethy-
leneimine (PEI), polymer-peptide hybrid (PEI600-Tat
conjugate) and also electroporation. At first, the level of
humoral and cellular immune responses were compared
by using HPV16 E7 + Gp96 co-injection as DNA/DNA
and prime-boost (DNA/ protein) immunization strate-
gies in C57BL/6 mice model. Assessment of cellular
immune responses against E7 antigen indicated that co-
delivery of naked DNA E7 + Gp96 plasmid is immuno-
logically more effective than E7 alone and induces Th1
response [1,2].
Furthermore, in another study we demonstrated that
PEI600-Tat conjugate is efficient to improve immune
responses in vivo. Indeed, PEI600-Tat/E7DNA complex
at certain ratio induced IFN-g response slightly more
than that GP96 adjuvant [3]. In our recent study, we are
attempting to develop a novel, non-pathogenic, parasitic
vector, Leishmania tarentolae, as a recombinant live
HPV vaccine candidate expressing HPV16 E7 and evalu-
ate its ability to elicit E7-specific T cell responses in
mice model as compared to E7 DNA vaccine. Moreover,
ap r e v e n t i v ea n dt h e r a p e u t i cD N Av a c c i n eh a sb e e n
generated using HPV16 E7 co-linked to N-terminal frag-
ment of GP96 and chemokines delivered by chemical
system (PEI600-Tat conjugate) and/or physical method
(electroporation). Altogether, combining new and
improved immunotherapeutic strategies are crucial for
enhancing long-term immune responses in patients.
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